DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses growth accelerates
Q1 FY2026 other income / expenses of $447K rose 0.9% year over year, ahead of the -21.3% change in trailing-twelve-month other income / expenses. Sequentially, it fell 7.5% from the prior quarter. Over 3 fiscal years it compounded at +67.5% a year.
Context
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +0.9% holds above the trailing-twelve-month pace of -21.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 1.66M USD
- Year-over-year change
- -26.8%
- 4-year CAGR
- +112.1%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.66M | -26.8% |
| FY2024 | 2024-12-31 | 2.27M | +17.5% |
| FY2023 | 2023-12-31 | 1.93M | +446.5% |
| FY2022 | 2022-12-31 | 353K | +330.5% |
| FY2021 | 2021-12-31 | 82K | — |
Other Income / Expenses vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's LTM Mar 2026 other income / expenses of $1.66M is the 5th highest of the 7 companies compared; the peer median is $11.64M.
- Its year-over-year change of -21.3% is the 4th highest of 7, against a peer median of -19.7%.
- Over three fiscal years its annual growth of +67.5% compares with a peer median of +42.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $31.35M | -42.6% | +42.7% | 869.8% | |
| LTM Mar 2026 | $12.09M | -36.1% | +33.8% | 1360.4% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $11.78M | +9.2% | +266.7% | 114.2% |
| LTM Mar 2026 | $11.51M | +295.2% | — | 57.5% | |
| LTM Mar 2026 | $1.66M | -21.3% | +67.5% | — | |
| LTM Mar 2026 | -$9.98M | -163.6% | — | — | |
| LTM Mar 2026 | -$24.05M | -3.3% | — | 10.3% | |
| Peer median (excluding DMAC) | $11.64M | -19.7% | +42.7% | 114.2% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 8.77M | 7.84M | 13.11M | 19.06M | 24.61M |
| Selling, General & Admin | 4.88M | 6.16M | 8.16M | 7.62M | 9.78M |
| Operating Expenses | 13.65M | 14M | 21.27M | 26.68M | 34.4M |
| Depreciation & Amortization | 24K | 25K | 30K | 39K | 43K |
| EBITDA | (13.54M) | (13.62M) | (19.31M) | (24.38M) | (32.7M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (13.65M) | (14M) | (21.27M) | (26.68M) | (34.4M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 2.3M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 82K | 353K | 1.93M | 2.27M | 1.66M |
| Income Before Tax | (13.56M) | (13.65M) | (19.34M) | (24.41M) | (32.74M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 28K | 28K | 43K | 30K | 28K |
| Net Income | (13.59M) | (13.68M) | (19.38M) | (24.44M) | (32.77M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.65) | (0.52) | (0.60) | (0.60) | (0.70) |
| EPS (Diluted) | (0.65) | (0.52) | (0.60) | (0.60) | (0.70) |
| Weighted Avg Shares | 20.77M | 26.44M | 32.57M | 40.4M | 46.98M |
| Weighted Avg Shares (Diluted) | 20.77M | 26.44M | 32.57M | 40.4M | 46.98M |
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.